I-MAB (NAS:IMAB)
$ 1.055 -0.04 (-3.64%) Market Cap: 81.84 Mil Enterprise Value: -118.19 Mil PE Ratio: 0 PB Ratio: 0.35 GF Score: 35/100

Full Year 2020 I-Mab Earnings Call Transcript

Mar 29, 2021 / 12:00PM GMT
Release Date Price: $44.38 (-4.80%)
Operator

Good day, ladies and gentlemen. Thank you for standing by, and welcome to the I-Mab Biopharma 2020 Financial Results and Business Update Conference Call. (Operator Instructions).

It is now my pleasure to turn the conference over Jielun Zhu, I-Mab's Chief Financial Officer and Director. Please go ahead, sir.

Jielun Zhu
I-Mab - CFO & Director

All right. Thank you, operator. Everyone, welcome to the I-Mab 2020 Full Year Financial Results and Business Update Conference Call. Earlier today, we issued a press release providing a review of our financial results for the full year ended December 31, 2020 as well as an overview of our recent corporate highlights and upcoming milestones. The press release can be accessed on the investors portion of our corporate website.

Joining me today on the call from I-Mab's senior management team are Dr. Jingwu Zang, our Founder, Chairman and Director; Dr. Joan Shen, our Chief Executive Officer and Director; and Mr. Yifei Zhu, our Chief Commercial Officer.

Dr. Zang will provide a high-level overview

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot